US2016199324A1PendingUtilityA1
Multiple myeloma treatment
Est. expiryAug 22, 2033(~7.1 yrs left)· nominal 20-yr term from priority
G01N 2800/52G01N 2333/4739A61P 35/00A61K 9/0019A61K 31/165A61K 9/0053G01N 33/5751
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
Claims
exact text as granted — not AI-modified1 . A method of treating multiple myeloma (MM) in an individual, the method comprising:
administering to the individual an effective amount of trichostatin A (TSA).
2 . The method of claim 1 , wherein the effective amount is an amount sufficient to decrease expression of at least one gene in the individual, the at least one gene being selected from a group consisting of: CCNB1, AURKB, CDC2, BIRC5, KIF11, KIF2C, TOP2A, ASPM, CKS1B, and WEE1.
3 . The method of claim 2 , wherein the effective amount is an amount sufficient to decrease expression of either or both of CCNB1 and AURKB in the individual.
4 . The method of claim 2 , wherein the effective amount is an amount sufficient to decrease expression of either or both of CKS1B and WEE1.
5 . The method of claim 2 , wherein the effective amount is an amount sufficient to decrease expression of each of CCNB1, AURKB, CDC2, BIRC5, KIF11, KIF2C, TOP2A, ASPM, CKS1B, and WEE1.
6 . The method of claim 1 , wherein the effective amount is between about 0.01 mg/kg/day and about 100 mg/kg/day.
7 . The method of claim 1 , wherein the effective amount is between about 0.1 mg/kg/day and about 10 mg/kg/day.
8 . The method of claim 7 , wherein the effective amount is between about 0.5 mg/kg/day and about 5 mg/kg/day.
9 . The method of claim 1 , wherein administering includes orally administering.
10 . The method of claim 1 , wherein administering includes intravenously administering.
11 . A method of treating multiple myeloma (MM) in an individual, the method comprising:
determining, from a biological sample obtained from the individual's body, a level of expression of one or more gene in the individual, the one or more gene selected from a group consisting of: CCNB1, AURKB, CDC2, BIRC5, KIF11, KIF2C, TOP2A, ASPM, CKS1B, and WEE1; and in the case that the level of expression of the one or more gene is indicative of overexpression, administering to the individual an effective amount of trichostatin A (TSA).
12 . The method of claim 11 , wherein the effective amount is an amount sufficient to decrease expression of at least one gene in the individual, the at least one gene being selected from a group consisting of: CCNB1, AURKB, CDC2, BIRC5, KIF11, KIF2C, TOP2A, ASPM, CKS1B, and WEE1.
13 . The method of claim 12 , wherein the effective amount is an amount sufficient to decrease expression of either or both of CCNB1 and AURKB in the individual.
14 . The method of claim 12 , wherein the effective amount is an amount sufficient to decrease expression of either or both of CKS1B and WEE1.
15 . The method of claim 12 , wherein the effective amount is an amount sufficient to decrease expression of each of CCNB1, AURKB, CDC2, BIRC5, KIF11, KIF2C, TOP2A, ASPM, CKS1B, and WEE1.
16 . The method of claim 11 , wherein the effective amount is between about 0.01 mg/kg/day and about 100 mg/kg/day.
17 . The method of claim 16 , wherein the effective amount is between about 0.1 mg/kg/day and about 10 mg/kg/day.
18 . The method of claim 17 , wherein the effective amount is between about 0.5 mg/kg/day and about 5 mg/kg/day.
19 . The method of claim 11 , wherein administering includes orally administering.
20 . The method of claim 11 , wherein administering includes intravenously administering.
21 - 42 . (canceled)Join the waitlist — get patent alerts
Track US2016199324A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.